Professor Jeremy Hobart
Profiles

Professor Jeremy Hobart

Professor

Peninsula Medical School (Faculty of Health)

Professor Jeremy Hobart can be contacted through arrangement with our Press Office, to speak to the media on these areas of expertise.
  • Clinical trials
  • Psychometrics
  • Rating scale science
  • Health outcomes
  • Health measurement
  • Multiple Sclerosis diagnosis
  • Multiples Sclerosis management
  • Clinical neurology
Biography

Biography

  • Consultant Neurologist Plymouth Hospitals NHS Trust
  • Professor of Clinical Neurology and Health Measurement Plymouth University Peninsula Schools of Medicine and Dentistry

Qualifications

Jeremy Hobart BSc PhD FRCP Dip Public Health

Dr Jeremy Hobart is a Consultant Neurologist at Derriford Hospital, and Professor at the Plymouth University Peninsula Schools of Medicine and Dentistry. His clinical sub-specialist interest is the diagnosis and management of people with multiple sclerosis. His medical training was at St Mary’s Hospital Medical School in London, and neurology training was undertaken predominantly at the National Hospital for Neurology and Neurosurgery, Queen Square. He is also President of the South Devon branch of the MS Society.

Jeremy Hobart’s research interest is rating scales for measuring health outcomes. His training in health measurement and rating scale science has included a PhD in Psychometrics from the London School of Hygiene and Tropical Medicine (Prof Donna Lamping), and post doctoral attachments to the University of Chicago (Prof Ben Wright) and, more recently, a secondment to Murdoch University Perth, Western Australia (Prof David Andrich) sponsored by a Royal Society of Medicine Ellison-Cliffe Travelling Fellowship.

By a combination of chance and design, this training means that Jeremy is one of only a handful of clinicians formally trained in rating scale science. He has led the development of a number of rating scales, has published widely in this area, and holds over £7 million in research grants.

Jeremy Hobart is a Consultant Neurologist at Plymouth Hospitals NHS Trust, and Professor in Clinical Neurology and Health Measurement at the Plymouth University Peninsula Schools of Medicine and Dentistry.

Key publications

Cano SJ, Riazi A, Schapira AHV, Cooper JM & Hobart JC (2009) 'Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies' Mov Disord 24, (7) 984-992 Author Site , DOI
Hobart J & Cano S (2009) 'Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods' Health Technol Assess 13, (12) iii-177 Author Site , DOI
(2011) 'Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis' Nature 476, (7359) 214-219 , DOI Open access
Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T & Hobart JC (2010) 'The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts' J Neurol Neurosurg Psychiatry 81, (12) 1363-1368 Author Site , DOI
Hobart JC, Cano SJ & Thompson AJ (2010) 'Effect sizes can be misleading: is it time to change the way we measure change?' J Neurol Neurosurg Psychiatry 81, (9) 1044-1048 Author Site , DOI
View all publications
Publications

Publications

Key publications

Cano SJ, Riazi A, Schapira AHV, Cooper JM & Hobart JC (2009) 'Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies' Mov Disord 24, (7) 984-992 Author Site , DOI
Hobart J & Cano S (2009) 'Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods' Health Technol Assess 13, (12) iii-177 Author Site , DOI
(2011) 'Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis' Nature 476, (7359) 214-219 , DOI Open access
Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T & Hobart JC (2010) 'The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts' J Neurol Neurosurg Psychiatry 81, (12) 1363-1368 Author Site , DOI
Hobart JC, Cano SJ & Thompson AJ (2010) 'Effect sizes can be misleading: is it time to change the way we measure change?' J Neurol Neurosurg Psychiatry 81, (9) 1044-1048 Author Site , DOI

Key publications are highlighted

Journals
Articles
Chen B, Gomez-Figueroa E, Redenbaugh V, Francis A, Satukijchai C, Wu Y, Messina S, Sa M, Woodhall M & Robertson NP (2023) 'Do Early Relapses Predict the Risk of Long‐Term Relapsing Disease in an Adult and Paediatric Cohort with <scp>MOGAD</scp>?' Annals of Neurology , DOI Open access
Lerede A, Rodgers J, Middleton RM, Hampshire A, Nicholas R, Coles A, Chataway J, Duddy M, Emsley H & Ford H (2023) 'Patient-reported outcomes in multiple sclerosis: a prospective registry cohort study' Brain Communications 5, (4) , DOI Open access
Close J, Vandercappellen J, King M & Hobart J (2023) 'Measuring Fatigue in Multiple Sclerosis: There may be Trouble Ahead' Neurology and Therapy , DOI Open access
Williams T, John N, Calvi A, Bianchi A, De Angelis F, Doshi A, Wright S, Shatila M, Yiannakas MC & Chowdhury F (2023) 'Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross‐sectional analysis from the <scp>MS‐STAT2</scp> randomized controlled trial' European Journal of Neurology 30, (9) 2769-2780 , DOI Open access
Hobart J, Chitnis T, Oh J, Burke L, King M, Vo P, Vandercappellen J & Lloyd A (2023) 'Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selection' Multiple Sclerosis and Related Disorders 76, , DOI Open access
Rinderknecht MD, Zanon M, Boonstra TA, Angelini L, Stanev D, Chan GG, Bunn L, Dondelinger F, Hosking R & Freeman J (2023) 'An observational study to assess validity and reliability of smartphone sensor-based gait and balance assessments in multiple sclerosis: Floodlight GaitLab protocol' DIGITAL HEALTH 9, , DOI Open access
Perfetto EM, Burke L, Love TR, Schrandt MS & Hobart J (2022) 'Measuring Health and Well-Being: We Need to Get it Right for Patients, With Patients' Value in Health 26, (3) 435-437 , DOI
Hobart J, Butzkueven H, Haartsen J, Ziemssen T, Lane T & Giovannoni G (2022) 'Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool' Multiple Sclerosis Journal - Experimental, Translational and Clinical 8, (3) , DOI Open access
Bharadia T, Vandercappellen J, Chitnis T, Eelen P, Bauer B, Brichetto G, Lloyd A, Schmidt H, King M & Fitzgerald J (2022) 'Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?' Multiple Sclerosis Journal - Experimental, Translational and Clinical 8, (2) 205521732211056-205521732211056 , DOI Open access
Dobson R, Craner M, Waddingham E, Miller A, Pindoria J, Cavey A, Blain C, De Luca G, Evangelou N & Ford H (2022) 'Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)' Multiple Sclerosis and Related Disorders 63, , DOI Open access
Zaratin P, Vermersch P, Amato MP, Brichetto G, Coetzee T, Cutter G, Edan G, Giovannoni G, Gray E & Hartung HP (2022) 'The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions' Multiple Sclerosis and Related Disorders 61, 103757-103757 , DOI
Satukijchai C, Mariano R, Messina S, Sa M, Woodhall MR, Robertson NP, Ming L, Wassmer E, Kneen R & Huda S (2022) 'Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease in the United Kingdom' JAMA Network Open 5, (1) , DOI Open access
Hupperts R, Gasperini C, Lycke J, Ziemssen T, Feys P, Xiao S, Acosta C, Koster T & Hobart J (2022) 'Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE' Therapeutic Advances in Neurological Disorders 15, , DOI Open access
Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Webb S, Hemingway C, Hobart J, Evangelou N & Scolding N (2021) 'OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis' BMJ Open 11, (11) , DOI Open access
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M, Giovannoni G & Macdougall A (2021) 'Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study' Multiple Sclerosis and Related Disorders 57, 103409-103409 , DOI
Rodgers J, Friede T, Vonberg FW, Constantinescu CS, Coles A, Chataway J, Duddy M, Emsley H, Ford H & Fisniku L (2021) 'The impact of smoking cessation on multiple sclerosis disease progression' Brain , DOI Open access
Hobart J (2021) 'Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax): Evaluation of Measurement Performance' Journal of drugs in dermatology : JDD , DOI Open access
Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X, Yildiz O & Adams A (2021) 'Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients' Therapeutic Advances in Neurological Disorders 14, , DOI Open access
Ziemssen T, Bass A, Berkovich R, Comi G, Eichau S, Hobart J, Hunter SF, LaGanke C, Limmroth V & Pelletier D (2020) 'Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study' CNS Drugs , DOI Open access
Sá MJ, Soares dos Reis R, Altintas A, Celius EG, Chien C, Comi G, Graus F, Hillert J, Hobart J & Khan G (2020) 'State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis' Neurology and Therapy , DOI Open access
Hobart J & Giovannoni G (2020) 'Cognition and its relation to brain health in patients with MS: Response to letter' Multiple Sclerosis Journal 26, (12) 1613-1614 , DOI Open access
Lin S, Green H, Hendy P, Heerasing N, Chanchlani N, Hamilton B, Walker G, Heap G, Hobart J & Martin R (2020) 'Clinical features and genetic risk of demyelination following anti-TNF treatment' Journal of Crohn's and Colitis , DOI Open access
Close J, Baines K, Burke L & Hobart J (2020) 'Measuring upper limb function in MS: Which existing patient reported outcomes are fit for purpose?' eNeurologicalSci 19, 100237-100237 , DOI Open access
Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D & Prados Carrasco F (2020) 'Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial' The Lancet Neurology 19, (3) 214-225 , DOI Open access
Giovannoni G, Airas L, Bove R, Boyko A, Cutter G, Hobart J, Kuhle J, Oh J, Tur C & Garas M (2019) 'Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091)' Neurology 92, (15_supplement) Publisher Site , DOI
Hobart JC, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V & McNeill M (2018) 'Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine' CNS Drugs 33, (1) 61-79 , DOI Open access
Germon T, Clifford D, Lee W & Hobart J (2018) 'Low back pain' The Lancet 392, (10164) 2547-2547 , DOI Open access
Hobart JC (2018) 'International consensus on quality standards for brain health-focused care in multiple sclerosis' Multiple Sclerosis Journal , DOI Open access
Hobart J, Bowen A, Pepper G, Crofts H, Eberhard L, Berger T, Boyko A, Boz C, Butzkueven H & Celius EG (2018) 'International consensus on quality standards for brain health-focused care in multiple sclerosis' Multiple Sclerosis 1352458518809326-1352458518809326 Author Site , DOI Open access
Albrecht P, Bjorna IK, Brassat D, Farrell R, Feys P, Hobart JC, Hupperts R, Linnebank M, Magdic J & Oreja-Guevara C (2018) 'Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience – report of an expert meeting' Therapeutic Advances in Neurological Disorders , DOI Open access
Kirsch BM, Burke L, Hobart J, Angulo D & Walker PS (2018) 'The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content' Journal of Drugs in Dermatology Open access
Middleton RM, Rodgers WJ, Chataway J, Schmierer K, Rog D, Galea I, Akbari A, Tuite-Dalton K, Lockhart-Jones H & Griffiths D (2018) 'Validating the portal population of the United Kingdom Multiple Sclerosis Register' Multiple Sclerosis and Related Disorders 24, 3-10 , DOI
Kapoor R, Ho P-R, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL & Freedman MS (2018) 'Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension' The Lancet Neurology 17, (5) 405-415 , DOI
Hobart JC, Hussein D, Yusef T & Murat T (2017) 'Testing patient-reported outcome measurement equivalence in multinational clinical trials: An exemplar using the 12-item Multiple Sclerosis Walking Scale' Multiple Sclerosis Journal - Experimental, Translational and Clinical 3, (3) , DOI Open access
Powers JH, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, Isaac M, Vamvakas S, Slagle A & Molsen E (2017) 'Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force' Value in Health 20, (1) 2-14 , DOI
Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S & Coyle PK (2016) 'Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?' Multiple Sclerosis Journal 23, (4) 604-613 , DOI Open access
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T (2016) 'Brain health: time matters in multiple sclerosis' Multiple Sclerosis and Related Disorders 9, S5-S48 , DOI Open access
Ofori J, Freeman J, Logan A, Rapson R, Zajieck J, Hobart J & Marsden JF (2016) 'An investigation of commonly prescribed stretches of the ankle plantarflexors in people with Multiple Sclerosis' Clinical Biomechanics 37, 22-26 , DOI Open access
Hobart J (2016) 'Measuring spinal surgical success: the proportion achieving acceptable symptoms' The Spine Journal 16, (4) S19-S20 , DOI Open access
Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D & Watson C (2015) 'Measuring the Impact of Multiple Sclerosis: Enhancing the Performance of the Msis-29 and Msws-12' Value in Health 18, (7) A709-A710 , DOI
Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D & Watson C (2015) 'Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36' Value in Health 18, (7) A713-A713 , DOI
Walton MK, Powers JH, Hobart J, Patrick D, Marquis P, Vamvakas S, Isaac M, Molsen E, Cano S & Burke LB (2015) 'Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force' Value in Health 18, (6) 741-752 , DOI
Mehta L, McNeill M, Hobart J, Wyrwich KW, Poon J-L, Auguste P, Zhong J & Elkins J (2015) 'Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results' Multiple Sclerosis Journal - Experimental, Translational and Clinical 1, , DOI Open access
Baker K, Barrett L, Playford ED, Aspden T, Riazi A & Hobart J (2015) 'Measuring arm function early after stroke: is the DASH good enough?' Journal of Neurology, Neurosurgery & Psychiatry 87, (6) 604-610 , DOI Open access
Germon T & Hobart J (2015) 'People receiving unnecessary treatments: accurate diagnosis is key' BMJ 350, (jun02 26) h2962-h2962 , DOI
Cano S, Cleanthous S, Marquis P, Hobart J, Naoshy S, Mikol D, Petrillo J, Steiner D, Chen Y & Watson C (2015) 'Measuring Upper Limb Function In Multiple Sclerosis: Enhancing The Abilhand’s Performance' Value in Health 18, (3) A24-A24 , DOI
Mehta L, McNeill M, Hobart J, Wyrwich K, Poon JL, Auguste P, Zhong J & Elkins J (2015) 'Identifying a Minimally Important Change Threshold for The Multiple Sclerosis Walking Scale-12 (MSWS-12)' MULTIPLE SCLEROSIS JOURNAL 21, (6) 813-814 Author Site Open access
Petrillo J, Hobart J, Balcer L, Chai Y, Xu L & Cadavid D (2015) 'Effects of Anti-LINGO-1 Monoclonal Antibody BIIB033 on Vision-Related Quality-of-Life in Subjects with Acute Optic Neuritis: Results from the RENEW Study (P7.213)' Neurology 84, (14_supplement) Publisher Site , DOI
Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S & Coyle P (2015) 'How Satisfied with Their Treatment Are Patients with MS? Psychometric Evaluation of the Treatment Satisfaction Questionnaire for Medication (TSQM) (P3.236)' Neurology 84, (14_supplement) Publisher Site , DOI
Barrett L, Cano S, Zajicek J & Hobart J (2015) 'Lending a hand: can DASH items help ABILHAND improve manual ability measurement in multiple sclerosis?' Mult Scler 21, (5) 612-621 Author Site , DOI
Germon TJ & Hobart JC (2015) 'Definitions, diagnosis, and decompression in spinal surgery: problems and solution' Spine J 15, (3 Suppl) S5-S8 Author Site , DOI
Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D & Miller D (2015) 'The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis' Health Technol Assess 19, (12) vii-187 Author Site , DOI
Hartung H-P, Barkhof F, Fernandez O, Hobart J, Giovannoni G, Sormani MP, Dadon Y, Sasson N & Knappertz V (2014) 'A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Laquinimod 0.6mg or 1.2mg QD versus IFNβ-1a in Patients with Relapsing Remitting Multiple Sclerosis (P3.153)' Neurology 82, (10_supplement) Publisher Site , DOI
Germon T, Singleton W & Hobart J (2014) 'Is NICE guidance for identifying lumbar nerve root compression misguided?' Eur Spine J 23 Suppl 1, (Suppl 1) S20-S24 Author Site , DOI
Hobart J, Cano S, Baron R, Thompson A, Schwid S, Zajicek J & Andrich D (2013) 'Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis' Mult Scler 19, (13) 1773-1783 Author Site , DOI Open access
Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, Gomez Cano M, McManus D, Mallik S & Hobart J (2013) 'Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial' Lancet Neurology 2013, 1-9 , DOI
Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VAG, Vittori D, Fornasiero A, Buscarinu MC & Romano S (2013) 'A “Candidate-Interactome” Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis' PLoS ONE 8, (5) e63300-e63300 , DOI Open access
Barrett LE, Cano SJ, Zajicek JP & Hobart JC (2013) 'Can the ABILHAND handle manual ability in MS?' Mult Scler 19, (6) 806-815 Author Site , DOI
Hobart J, Blight AR, Goodman A, Lynn F & Putzki N (2013) 'Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS' Neurology 80, (16) 1509-1517 Author Site , DOI
Freeman J, Walters R, Ingram W, Slade A, Hobart J & Zajicek J (2013) 'Evaluating change in mobility in people with multiple sclerosis: relative responsiveness of four clinical measures' Mult Scler 19, (12) 1632-1639 Author Site , DOI
Hobart J, Gilkes C, Adams W & Germon T (2013) 'Interspinous spacers for lumbar foraminal stenosis: formal trials are justified' Eur Spine J 22 Suppl 1, (Suppl 1) S47-S53 Author Site , DOI
Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J & Alzheimer's Disease Neuroimaging Initiative (2013) 'Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods' Alzheimers Dement 9, (1 Suppl) S4-S9 Author Site , DOI
Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J & Alzheimer's Disease Neuroimaging Initiative (2013) 'Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory' Alzheimers Dement 9, (1 Suppl) S10-S20 Author Site , DOI
Posner HB, Cano S, Carrillo MC, Selnes O, Stern Y, Thomas RG, Zajicek J & Hobart J (2013) 'Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: A new approach' Alzheimer's &amp; Dementia 9, (1S) , DOI
Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D & Goris A (2013) 'Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis' NATURE GENETICS 45, (11) 1353-+ , DOI
Hobart JC, Cano SJ, Warner TT & Thompson AJ (2012) 'What sample sizes for reliability and validity studies in neurology?' J Neurol 259, (12) 2681-2694 Author Site , DOI
Zajicek JP, Hobart JC, Slade A, Barnes D, Rickards C & Mattison P (2012) 'Multiple Sclerosis and Extract of Cannabis (MUSEC) – a randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in multiple sclerosis' Journal of Neurology, Neurosurgery and Psychiatry 83, 1125-1132 Publisher Site , DOI
Apostu V, Zajicek J & Hobart J (2012) '125 Campath-1H for multiple sclerosis: a pain in the neck?' Journal of Neurology, Neurosurgery &amp; Psychiatry 83, (3) e1.76-e1 , DOI
Bladh S, Nilsson MH, Hariz G-M, Westergren A, Hobart J & Hagell P (2012) 'Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's disease' JOURNAL OF NEUROLOGY 259, (4) 729-738 , DOI
Riazi A, Porter B, Chataway J, Thompson AJ & Hobart JC (2011) 'A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS)' Health Qual Life Outcomes 9, Author Site , DOI Open access
(2011) 'Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis' Nature 476, (7359) 214-219 , DOI Open access
Cano S, Barrett L, Zajicek J & Hobart J (2011) 'Dimensionality is a relative concept' Mult Scler 17, (7) 893-894 , DOI
Cano SJ, Barrett LE, Zajicek JP & Hobart JC (2011) 'Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis' Mult Scler 17, (2) 214-222 Author Site , DOI
Hobart J (2011) 'Multiple Sclerosis Walking Scale (MSWS-12): changes on all items are not equal' MULTIPLE SCLEROSIS JOURNAL 17, S92-S93
Hobart J (2011) 'Multiple Sclerosis Walking Scale (MSWS-12): exactly what clinical benefits do prolonged-release fampridine responders actually get?' MULTIPLE SCLEROSIS JOURNAL 17, S319-S320
McGuigan C, Schapiro R, Putzki N & Hobart J (2011) 'Responses to items of the MSWS-12 differ depending on EDSS and the impact of prolonged-release fampridine on walking speed' MULTIPLE SCLEROSIS JOURNAL 17, S473-S474
Cano SJ & Hobart JC (2011) 'The problem with health measurement' Patient Prefer Adherence 5, 279-290 Author Site , DOI Open access
Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T & Hobart JC (2010) 'The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts' J Neurol Neurosurg Psychiatry 81, (12) 1363-1368 Author Site , DOI
Zajicek JP, Ingram WM, Vickery J, Creanor S, Wright DE & Hobart JC (2010) 'Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort' BMC Neurol 10, Author Site , DOI Open access
Hobart JC, Cano SJ & Thompson AJ (2010) 'Effect sizes can be misleading: is it time to change the way we measure change?' J Neurol Neurosurg Psychiatry 81, (9) 1044-1048 Author Site , DOI
Hobart J (2010) 'F5‐01‐02: ADAS‐cog reanalyses' Alzheimer's &amp; Dementia 6, (4S_Part_6) , DOI
Littleton ET, Hobart JC & Palace J (2010) 'Modafinil for multiple sclerosis fatigue: Does it work?' CLINICAL NEUROLOGY AND NEUROSURGERY 112, (1) 29-31 , DOI
Freeman RG, Cano S, Slade A, Delatycki M, Tai G & Hobart J (2010) 'Cross-cultural Comparisons: Lessons from Friedreich's Ataxia' QUALITY OF LIFE RESEARCH 19, 64-65
Slade AL, Zajicek JP, Ingram WM, Freeman RG, Cano S & Hobart JC (2010) 'Does a Rasch-modified FSS deliver better measurements?' QUALITY OF LIFE RESEARCH 19, 89-89
Cano SJ & Hobart JC (2010) 'Validity in fatigue measurement: complementing quality and quantity' QUALITY OF LIFE RESEARCH 19, 14-14
Cano S, Posner H, Aisen P, Selnes O, Stern Y, Thomas R, Weiner M, Zajicek J, Zeger S & Hobart J (2009) 'O4‐04‐07: The ADAS‐cog's performance as a measure—lessons from the ADNI study: Part 2 ‐ evaluation using modern psychometric methods' Alzheimer's &amp; Dementia 5, (4S_Part_5) , DOI
Posner H, Cano S, Aisen P, Selnes O, Stern Y, Thomas R, Weiner M, Zajicek J, Zeger S & Hobart J (2009) 'P1‐269: The ADAS‐cog's performance as a measure ‐ lessons from the ADNI study: Part 1 ‐ evaluation using traditional psychometric methods' Alzheimer's &amp; Dementia 5, (4S_Part_9) , DOI
Hobart J, Posner H, Aisen P, Selnes O, Stern Y, Thomas R, Weiner M, Zajicek J, Zeger S & Cano S (2009) 'P1‐270: The ADAS‐cog's performance as a measure ‐ lessons from the ADNI study: Part 3 ‐ do the scale modifications add value?' Alzheimer's &amp; Dementia 5, (4S_Part_9) , DOI
Cano SJ, Riazi A, Schapira AHV, Cooper JM & Hobart JC (2009) 'Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies' Mov Disord 24, (7) 984-992 Author Site , DOI
Posner H, Cano S, Aisen P, Selnes O, Stern Y, Thomas R, Weiner M, Zajicek J, Zeger S & Hobart J (2009) 'The ADAS-cog's Performance as a Measure- Lessons from the ADNI study. Part 1 Evaluation using traditional Psychometric Methods AAN' Neurology (72)
Hobart J & Cano S (2009) 'Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods' Health Technol Assess 13, (12) iii-177 Author Site , DOI
Osmani D, Rajagopalan K & Hobart J (2009) 'LINGUISTIC VALIDATION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29) FOR USE IN 29 LANGUAGES' VALUE IN HEALTH 12, (7) A371-A371 , DOI
van der Linden FAH, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ (2009) 'The size of the treatment effect: do patients and proxies agree?' BMC NEUROLOGY 9, , DOI Open access
Cano SJ, Warner TT, Thompson AJ, Bhatia KP, Fitzpatrick R & Hobart JC (2008) 'The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?' Health Qual Life Outcomes 6, Author Site , DOI Open access
Cano SJ & Hobart JC (2008) 'Watch out, watch out, the FDA are about' Dev Med Child Neurol 50, (6) 408-409 Author Site , DOI
Cano S & Hobart J (2008) 'Item response' Psychologist 21, (2)
Hagell P, Tornqvist AL & Hobart J (2008) 'Testing the SF-36 in Parkinson's disease' JOURNAL OF NEUROLOGY 255, (2) 246-254 , DOI
Hobart JC & Cano SJ (2008) 'Rating scales for clinical studies in neurology: challenges and opportunities' US Neurology 4, (1)
Schrag A, Selai C, Mathias C, Low P, Hobart J, Brady N & Quinn NP (2007) 'Measuring health-related quality of life in MSA: the MSA-QoL' Mov Disord 22, (16) 2332-2338 Author Site , DOI
Hobart JC, Cano SJ, Zajicek JP & Thompson AJ (2007) 'Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations' Lancet Neurol 6, (12) 1094-1105 Author Site , DOI
Campbell J, Winder R, Richards SH & Hobart J (2007) 'Exploring the relationships between provision of welfare benefits advice and the health of elderly people: a longitudinal observational study and discussion of methodological issues' Health Soc Care Community 15, (5) 454-463 Author Site , DOI
Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ & Hobart J (2007) 'Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure' Neurology 69, (6) 555-563 Author Site , DOI
Cano SJ, Thompson AJ, Bhatia K, Fitzpatrick R, Warner TT & Hobart JC (2007) 'Evidence-based guidelines for using the short form 36 in cervical dystonia' Movement Disorders 22, (1) 122-126
Schrag A, Selai C, Mathias C, Low P, Hobart J, Brady N & Quinn NP (2007) 'Measuring health-related quality of life in MSA: The MSA-QoL' Movement Disorders 22, (16) 2332-2338
Katzenschlager R, Schrag A, Evans A, Manson A, Carroll CB, Ottaviani D, Lees AJ & Hobart J (2007) 'Quantifying the impact of dyskinesias in PD - The PDYS-26: A patient-based outcome measure' Neurology 69, (6) 555-563
Cano SJ, Thompson AJ, Bhatia K, Fitzpatrick R, Warner TT & Hobart JC (2007) 'Evidence-based guidelines for using the Short Form 36 in cervical dystonia' Mov Disord 22, (1) 122-126 Author Site , DOI
Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ & Warner TT (2006) 'CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia' Neurology 67, (12) 2230-2232 Author Site , DOI
Cano SJ, O'Connor RJ, Thompson AJ & Hobart JC (2006) 'Exploring disability rating scale responsiveness II: do more response options help?' Neurology 67, (11) 2056-2059 Author Site , DOI
Holland A, O'Connor RJ, Thompson AJ, Playford ED & Hobart JC (2006) 'Talking the talk on walking the walk: a 12-item generic walking scale suitable for neurological conditions?' J Neurol 253, (12) 1594-1602 Author Site , DOI
Baron R, Elashaal A, Germon T & Hobart J (2006) 'Measuring outcomes in cervical spine surgery: think twice before using the SF-36' Spine (Phila Pa 1976) 31, (22) 2575-2584 Author Site , DOI
Riazi A, Cano SJ, Cooper JM, Bradley JL, Schapira AHV & Hobart JC (2006) 'Coordinating outcomes measurement in ataxia research: do some widely used generic rating scales tick the boxes?' Mov Disord 21, (9) 1396-1403 Author Site , DOI
Chataway J, Porter B, Riazi A, Heaney D, Watt H, Hobart J & Thompson A (2006) 'Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomized controlled trial' American Journal of Ophthalmology 142, (3) 535-535 , DOI
Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, Poon Y, Bower J, Burn D & Hobart J (2006) 'Measuring quality of life in PSP: the PSP-QoL' Neurology 67, (1) 39-44 Author Site , DOI
Chataway JC, Porter D, Heaney D, Riazi, Watt H, Hobart JC & Thompson AJ (2006) 'Treating multiple sclerosis relapses at home or in hospital out-patients: a randomised controlled trial of intravenous steroid delivery' Lancet Neurology 7, (5) 565-571
Hobart, Chataway JC, Heaney D & Porter B (2006) 'Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial' The Lancet Neurology 5, (7) 565-571 , DOI
van der Linden FAH, Kragt JJ, Hobart JC, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ (2006) 'Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 77, (10) 1157-1162 , DOI
Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ & Zajicek JP (2006) 'Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88)' Brain 129, 224-234
Baron R, Elashaal A, Germon T & Hobart J (2006) 'Measuring outcomes in cervical spine surgery: Think twice before using the SF-36' Spine 31, (22) 2575-2584
Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, Poon Y, Bower J, Burn D & Hobart J (2006) 'Measuring quality of life in PSP - The PSP-QoL' Neurology 67, (1) 39-44
Holland A, O'Connor RJ, Thompson AJ, Playford ED & Hobart JC (2006) 'Talking the talk on walking the walk - A 12-item generic walking scale suitable for neurological conditions?' Journal of Neurology 253, (12) 1594-1602
Cano SJ, Hobart JC, Hart PE, Korlipara LVP, Schapira AHV & Cooper JM (2005) 'International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia?' Mov Disord 20, (12) 1585-1591 Author Site , DOI
Hobart, Riazi A, Styles IM & Thompson AJ (2005) 'Getting the measure of spasticity in Multiple Sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS - 89)' Brain 129, (1) 224-234 , DOI
Schrag A, Selai C, Quinn N & Hobart J (2005) 'Measuring health-related quality of life in patients with progressive supranuclear palsy' Neurocase 11, (4) 246-249 Author Site , DOI
Freeman JA, Hobart JC, Playford ED, Undy B & Thompson AJ (2005) 'Evaluating neurorehabilitation: lessons from routine data collection' J Neurol Neurosurg Psychiatry 76, (5) 723-728 Author Site , DOI
Hobart J (2005) 'How severe is chronic pain in multiple sclerosis?' NATURE CLINICAL PRACTICE NEUROLOGY 1, (2) 80-81 , DOI
Nicholl L, Hobart JC, Cramp AFL & Lowe-Strong AS (2005) 'Measuring quality of life in multiple sclerosis: not as simple as it sounds' MULTIPLE SCLEROSIS JOURNAL 11, (6) 708-712 , DOI
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R & Thompson AJ (2005) 'How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales' Journal of Neurology, Neurosurgery and Psychiatry 76, (11) 1539-1543 , DOI
Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D & Hobart J (2004) 'Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study' Neurology 63, (7) 1245-1250 Author Site , DOI
Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ & Warner TT (2004) 'Patient-based outcomes of cervical dystonia: a review of rating scales' Mov Disord 19, (9) 1054-1059 Author Site , DOI
O'Connor RJ, Cano SJ, Thompson AJ & Hobart JC (2004) 'Exploring rating scale responsiveness: does the total score reflect the sum of its parts?' Neurology 62, (10) 1842-1844 Author Site , DOI
Carroll C, Hobart J, Fox C, Teare L & Gibson J (2004) 'Stroke in Devon: knowledge was good, but action was poor' J Neurol Neurosurg Psychiatry 75, (4) 567-571 Author Site , DOI Open access
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R & Thompson AJ (2004) 'Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome' Health Technol Assess 8, (9) iii-48 Author Site , DOI
Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C & Thompson A (2004) 'Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite' Mult Scler 10, (1) 41-46 Author Site , DOI
Riazi A, Thompson AJ & Hobart JC (2004) 'Self-efficacy predicts self-reported health status in multiple sclerosis' Mult Scler 10, (1) 61-66 Author Site , DOI
Carroll CB, Bain PG, Teare L, Liu X, Joint C, Wroath C, Parkin SG, Fox P, Wright D & Hobart J (2004) 'Cannabis for dyskinesia in Parkinson disease - A randomized double-blind crossover study' Neurology 63, (7) 1245-1250
Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R & Hobart JC (2004) 'Capturing the true burden of dystonia on patients - The Cervical Dystonia Impact Profile (CDIP-58)' Neurology 63, (9) 1629-1633
O'Connor RJ, Cano SJ, Thompson AJ & Hobart JC (2004) 'Exploring rating scale responsiveness - Does the total score reflect the sum of its parts?' Neurology 62, (10) 1842-1844
Nicholl L, Hobart J, Dunwoody L, Cramp F & Lowe-Strong A (2004) 'Measuring disability in multiple sclerosis: is the Community Dependency Index an improvement on the Barthel Index?' MULTIPLE SCLEROSIS JOURNAL 10, (4) 447-450 , DOI
Nicholl L, Hobart J, Dunwoody L, Cramp F & Lowe-Strong A (2004) 'Measuring disability in multiple sclerosis: is the Community Dependency Index an improvement on the Barthel Index?' Multiple Sclerosis 10, (4) 447-450
Hobart J, Kalkers N, Barkhof F, Uitdehaag B, Polman C & Thompson A (2004) 'Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite' Multiple Sclerosis 10, (1) 41-46
Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ & Warner TT (2004) 'Patient-based outcomes of cervical dystonia: A review of rating scales' Movement Disorders 19, (9) 1054-1059
Hobart J (2003) 'Rating scales for neurologists' J Neurol Neurosurg Psychiatry 74 Suppl 4, (Suppl 4) iv22-iv26 Author Site , DOI
Riazi A, Hobart JC, Fitzpatrick R, Freeman JA & Thompson AJ (2003) 'Socio-demographic variables are limited predictors of health status in multiple sclerosis' J Neurol 250, (9) 1088-1093 Author Site , DOI
Mundy HR, Jones SJ, Hobart JC, Hanna MG & Lee PJ (2003) 'A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy' Neurology 61, (4) 528-530 Author Site , DOI
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R & Thompson AJ (2003) 'Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales' Mult Scler 9, (4) 411-419 Author Site , DOI
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Freeman JA, Jenkinson C, Peto V & Thompson AJ (2003) 'Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles' J Neurol Neurosurg Psychiatry 74, (6) 710-714 Author Site , DOI
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R & Thompson AJ (2003) 'Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12)' Neurology 60, (1) 31-36 Author Site , DOI
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R & Thompson AJ (2003) 'Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales' Multiple Sclerosis 9, (4) 411-419
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R & Thompson AJ (2003) 'Measuring the impact of MS on walking ability - The 12-Item MS Walking Scale (MSWS-12)' Neurology 60, (1) 31-36
Hobart J (2002) 'Measuring disease impact in disabling neurological conditions: are patients' perspectives and scientific rigor compatible?' Curr Opin Neurol 15, (6) 721-724 Author Site , DOI
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R & Thompson AJ (2002) 'Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples' J Neurol Neurosurg Psychiatry 73, (6) 701-704 Author Site , DOI
Edwards SGM, Playford ED, Hobart JC & Thompson AJ (2002) 'Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation' BMJ 324, (7352) Author Site , DOI
Hobart JC, Williams LS, Moran K & Thompson AJ (2002) 'Quality of life measurement after stroke: uses and abuses of the SF-36' Stroke 33, (5) 1348-1356 Author Site , DOI
Jenkinson C, Hobart J, Chandola T, Fitzpatrick R, Peto V, Swash M & ALS-HPS Steering Group. Amyotrophic Lateral Sclerosis Health Profile Study (2002) 'Use of the short form health survey (SF-36) in patients with amyotrophic lateral sclerosis: tests of data quality, score reliability, response rate and scaling assumptions' J Neurol 249, (2) 178-183 Author Site , DOI
Hobart J (2002) 'Measuring disease impact in disabling neurological conditions: are patients' perspectives and scientific rigor compatible?' Current Opinion in Neurology 15, (6) 721-724
Hobart JC, Williams LS, Moran K & Thompson AJ (2002) 'Quality of life measurement after stroke - Uses and abuses of the SF-36' Stroke 33, (5) 1348-1356
Hobart JC, Lamping DL, Freeman JA, Greenwood RJ, McLellan DL & Thompson A (2001) 'Evidence-based measurement: which disability scale for neurological rehabilitation?' Neurology 57, 639-644
Hobart J, Freeman J, Lamping D, Fitzpatrick R & Thompson A (2001) 'The SF-36 in multiple sclerosis: why basic assumptions must be tested' J Neurol Neurosurg Psychiatry 71, (3) 363-370 Author Site , DOI
Hobart JC & Thompson AJ (2001) 'The five item Barthel index' J Neurol Neurosurg Psychiatry 71, (2) 225-230 Author Site , DOI
Freeman JA, Hobart JC & Thompson AJ (2001) 'Does adding MS-specific items to a generic measure (the SF-36) improve measurement?' Neurology 57, (1) 68-74 Author Site , DOI
Manson AJ, Katzenschlager R, Hobart J & Lees AJ (2001) 'High dose naltrexone for dyskinesias induced by levodopa' J Neurol Neurosurg Psychiatry 70, (4) 554-556 Author Site , DOI
Hobart, Freeman JA, Lamping DL & Langdon DW (2001) 'Evidence-based measurement: which disability scale for neurologic rehabilitation?' Neurology 57, 639-644
Hobart, Fitzpatrick R, Lamping D & Riazi A (2001) 'The multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure' Brain 124, (5) 962-973 , DOI
Hobart J, Freeman J & Thompson A (2000) 'Kurtzke scales revisited: the application of psychometric methods to clinical intuition' Brain 123 ( Pt 5), 1027-1040 Author Site , DOI
Freeman JA, Hobart JC, Langdon DW & Thompson AJ (2000) 'Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis' J Neurol Neurosurg Psychiatry 68, (2) 150-156 Author Site , DOI
van der Putten JJ, Hobart JC, Freeman JA & Thompson AJ (1999) 'Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel index and the Functional Independence Measure' J Neurol Neurosurg Psychiatry 66, (4) 480-484 Author Site , DOI
Freeman JA, Langdon DW, Hobart JC & Thompson AJ (1999) 'Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?' Neurology 52, (1) 50-56 Author Site , DOI
Freeman JA, Langdon DW, Hobart JC & Thompson AJ (1998) '*The Impact of In-patient Rehabilitation on Disability and Handicap in Progressive Multiple Sclerosis: A randomised controlled trial' Physiotherapy 84, (8) 401-401 , DOI
Thompson AJ & Hobart JC (1998) 'Multiple sclerosis: assessment of disability and disability scales' J Neurol 245, (4) 189-196 Author Site , DOI
Freeman JA, Langdon DW, Hobart JC & Thompson AJ (1997) 'The impact of inpatient rehabilitation on progressive multiple sclerosis' Ann Neurol 42, (2) 236-244 Author Site , DOI
Hobart JC, Freeman JA & Lamping DL (1996) 'Physician and patient-oriented outcomes in progressive neurological disease: which to measure?' Curr Opin Neurol 9, (6) 441-444 Author Site , DOI
Freeman JA, Hobart JC & Thompson AJ (1996) 'Outcomes-based research in neurorehabilitation: the need for multidisciplinary team involvement' Disabil Rehabil 18, (2) 106-110 Author Site , DOI
Hobart JC, Lamping DL & Thompson AJ (1996) 'Evaluating neurological outcome measures: The bare essentials' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 60, (2) 127-130 , DOI
Hobart JC, Freeman JA & Lamping DL (1996) 'Evaluating outcome measurement instruments' MS Management 1, (2) 6-12
Freeman JA, Langdon DW, Hobart JC & Thompson AJ (1996) 'Health-related quality of life in people with multiple sclerosis undergoing inpatient rehabilitation' JOURNAL OF NEUROLOGIC REHABILITATION 10, (3) 185-194
Freeman JA, Langdon DW, Hobart JC & Thompson AJ (1995) 'Reduced Disability Following Rehabilitation in Patients with Progressive Multiple Sclerosis' Physiotherapy 81, (8) 457-457 , DOI
Freeman JA, Hobart JC, Langdon DW & Thompson AJ (1995) 'Immediate and long term effects of inpatient rehabilitation in progressive multiple sclerosis (MS): Initial report' Journal of Neuroimmunology 56-63, 52-52 , DOI
Dash P, Hobart J, Malik K, Janmohamed S & Hill-Smith A (1990) 'A view from the other side' Health Services Journal 100(5230),
Reviews
Hobart JC (2006) 'Handbook of Neurological Rating Scales' Journal of Neurology,Neurosurgery and Psychiatry (77)
Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R & Hobart JC (2004) 'Capturing the true burden of dystonia on patients: The Cervical Dystonia Impact Profile (CDIP-58)' Neurology 63, (9) 1629-1633 , DOI
Letters
Cano S & Hobart J (2008) 'Taking a lead against evil - Response' PSYCHOLOGIST 21, (2) 169-169
Hobart J (2007) 'Measuring outcomes in clinical trials of stroke: time for state-of-the-art clinical trials to reject state-of-the-ark rating scales' JOURNAL OF NEUROLOGY 254, (8) 1119-1119 , DOI
Hobart J & Thompson A (1997) 'A comparison of two neurologic scoring instruments for multiple sclerosis' JOURNAL OF NEUROLOGY 244, (1) 60-60
Chapters
Schrag A, Selai C, Mathias C, Low P, Hobart J & Quinn N (2011) 'Measuring quality of life in multiple system atrophy' Quality of Life Measurement in Neurodegenerative and Related Conditions Cambridge University Press 60-70 , DOI
Schrag A, Selai C, Quinn N, Hobart J, Lees AJ, Litvan I, Lang A, Bower J & Burn D (2011) 'Measuring quality of life in progressive supranuclear palsy' Quality of Life Measurement in Neurodegenerative and Related Conditions Cambridge University Press 52-59 , DOI
Hobart J & Cano S (2011) 'Rasch analysis' Quality of Life Measurement in Neurodegenerative and Related Conditions Cambridge University Press 147-164 , DOI
Hobart J (2011) 'The Multiple Sclerosis Impact Scale (MSIS-29)' Quality of Life Measurement in Neurodegenerative and Related Conditions Cambridge University Press 24-40 , DOI
Cano S & Hobart J (2006) 'Measuring multiple sclerosis rehabilitation outcomes' Neurological Rehabilitation of Multiple Sclerosis CRC Press 109-135 , DOI
Hobart J & Thompson AJ (2002) 'Measurement of neurological outcomes' Diseases of the Nervous System Cambridge University Press 105-117 , DOI
Hobart JC & Thompson AJ (2001) 'Assessment Measures and Clinical Scales' Clinical Trials in Neurology Springer London 17-28 , DOI
Hobart JC & Thompson AJ (1997) 'Clinical trials of multiple sclerosis' Interferon Therapy of Multiple Sclerosis 449-508
Conference Papers
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T (2016) 'Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access (P1.340)' Ovid Technologies (Wolters Kluwer Health) Publisher Site , DOI
Cano S, Cleanthous S, Kinter E, Hobart J, Marquis P, Petrillo J, Sabatella G & You X (2015) 'Measuring the impact of multiple sclerosis: enhancing the MSIS-29's performance' 622-622
Petrillo J, Cadavid D, Cano S, Cleanthous S, Kinter E, Marquis P, Mikol D, Naoshy S, Sabatella G & Steiner D (2015) 'Suboptimal disability measurement in multiple sclerosis clinical trials: limitations of existing patient-reported outcomes measures' 341-341
Ziemssen T, Hobart J, Feys P, Linnebank M, Goodman A, McNeill M, Zhong J & Mehta L (2015) 'Long-term efficacy and safety of prolonged-release fampridine treatment in patients with multiple sclerosis: design of the multicentre, randomised, double-blind, placebo-controlled ENHANCE study' 621-621
Pace A, Zajicek J & Hobart J (2014) 'RESPONSIVENESS OF MSMSS IN PROGRESSIVE MULTIPLE SCLEROSIS' , DOI
Mehta L, McNeill M, Hobart J, Wyrwich K, Poon JL, Auguste P, Zhong ZJ & Elkins J (2014) 'Identifying an important change threshold for the Multiple Sclerosis Walking Scale-12 (MSWS-12)' 410-411
Zajicek JP (2012) 'Results from the Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial' in Hobart J; Wright D; Ball S; Nunn A; Vickery J ABN Annual Meeting Brighton 5-/-0/20125-/-0/2012
Hobart J, Cano S, Ingram W & Zajicek J (2012) 'A new path for the MS Walking Scale: MSWS-12 version 2' 334-335
Hobart JC & Zajicek JP (2012) 'Cannabis as a symptomatic treatment for MS: clinically meaningful MUSEC to the stiffness and walking problems of people with MS' 247-247
Hobart JC, Cano SJ, Thompson AJ & Andrich D (2012) 'It's time to change the way we measure change: demonstration, explanation, recommendations' 32-32
Hobart J, Blight A, Lynn F & Putzki N (2011) 'The timed 25-foot walk as an outcome measure for clinical trials in multiple sclerosis: further evidence that a 20% change is clinically meaningful' 150-150
Pace A, Hobart JC & Zajicek JP (2010) 'GRADING STRENGTH IN MANUAL MUSCLE TESTING: BESPOKE WORKS BETTER' E61-E61 , DOI
Pace A, Hobart JC & Zajicek JP (2010) 'MEASUREMENT OF GLOBAL STRENGTH: STABLE CONCEPT, FLUID RULER' E60-E61 , DOI
Hobart J & Andrich D (2010) 'RANKIN SCALES FOR MEASURING STROKE OUTCOMES: IS IT TIME TO THROW IN THE TOWEL?' E67-E67 , DOI
Zajicek JP, Cano SJ, Barrett LE & Hobart JC (2010) 'Beyond traditional psychometric methods: Can Rasch help the DASH?' 35-35
Pace AA, Hughes RAC, van Schaik IN & Hobart JC (2009) 'COMBINING SENSORY MODALITIES WITHIN A SENSORY SUM SCORE: ARE WE PICKING UP GOOD VIBRATIONS?' , DOI
Pace AA, Hughes RAC, Van Schaik IN & Hobart JC (2009) 'MAKING THE MOST OF OLNS DATA: CAN WE GET MORE OUT OF WHAT WE PUT IN?' , DOI
Pace AA, Zajicek JP & Hobart JC (2009) 'OVERCOMING THE WEAKNESSES OF A RATING SCALE FOR MEASURING STRENGTH' , DOI
Pace AA, Hughes RAC, van Schaik IN & Hobart JC (2009) 'RANDOMISED TRIAL OF METHOTREXATE IN CIDP STUDY: DID THE MEASUREMENT OF STRENGTH PROVE TO BE A WEAKNESS?' , DOI
Pace AA, Zajicek JP & Hobart JC (2009) 'TOO MUCH OF A GOOD THING: THE UNRELIABILITY OF RELIABILITY STATISTICS' , DOI
Pace AA, Hughes RAC, van Schaik IN & Hobart JC (2009) 'COMBINING SENSORY MODALITIES WITHIN A SENSORY SUM SCORE: ARE WE PICKING UP GOOD VIBRATIONS?' 115-115
Pace AA, Hughes RAC, van Schaik IN & Hobart JC (2009) 'MAKING THE MOST OF ONLS DATA: CAN WE GET MORE OUT OF WHAT WE PUT IN?' 116-116
Pace AA, Hughes RAC, van Schaik IN & Hobart JC (2009) 'RANDOMISED TRIAL OF METHOTREXATE IN CIDP (RMC) STUDY: DID THE MEASUREMENT OF STRENGTH PROVE TO BE A WEAKNESS?' 116-117
Hobart JC, Pace A, Barrett LE, Zajicek JP & Cano SJ (2008) 'Lessons from the Cannabinoids in Multiple Sclerosis (CAMS) Study: part 2-what happens when the Ashworth scale makes the grade2' S281-S282
Pace A, Cano SJ, Barrett LE, Zajicek JP & Hobart JC (2008) 'Lessons front the Cannabinoids in Multiple Sclerosis (CAMS) Study : part 1-did Ashworth's scale make the grade?' S285-S285
Cano SJ, Barrett LE, Pace A, Zajicek JP & Hobart JC (2008) 'Measuring upper limb functioning in multiple sclerosis: is the Disabilities of Arm, Shoulder and Hand (DASH) fit for purpose?' S279-S279
Cano SJ, Posner HB, Moline M, Hurt SW & Hobart JC (2008) 'Is the ADAS-cog fit for purpose in clinical trials? Part 1 - basic measurement properties' 32-33
Hobart JC, Posner HB, Moline M, Hurt SW & Cano SJ (2008) 'Is the ADAS-cog fit for purpose in clinical trials? Part 2 - examination by AD severity' 33-34
van der Linden FAH, Kragt JJ, Hobart JC, van Bon MA, Klein M, Thompson AJ, van der Ploeg HM, Uitdehaag BMJ & Polman CH (2006) 'Longitudinal proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of MS on daily life over a period of two years' S86-S87
van der Linden FAH, Kragt JJ, Hobart JH, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ (2005) 'Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of MS on daily life' S100-S100
Hobart J (1999) 'Use of clinical scales' 27-30
Presentations and posters
Hobart JH Hobart JH 'Measuring with rating scales - principles of measurements'
van Ter Linden FAH, Kragt JJ, Hobart JH, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ van Ter Linden FAH, Kragt JJ, Hobart JH, Klein M, Thompson AJ, van der Ploeg HM, Polman CH & Uitdehaag BMJ 'Proxy measurements in MS: does patient's cognitive impairment influence patient-proxy agreement on disease impact?'
Cano SJ, Zajicek JP, Thompson AJ & Hobart JC Cano SJ, Zajicek JP, Thompson AJ & Hobart JC 'Beware all neurologists: The FDA's tough new requirements for rating scale performance are coming to a study near you soon'
Hobart JC, Thompson AJ, Zajicek JP & Cano SJ Hobart JC, Thompson AJ, Zajicek JP & Cano SJ 'Rating scale responsiveness: Its time to change the way we measure change'
Hobart JC & Cano SJ Hobart JC & Cano SJ 'Sample size calculations for evaluating neurological rating scales: How many is enough?'
Cano SJ & Hobart JC Cano SJ & Hobart JC 'Selecting the right rating scale: Do neurologists have to have what they're given or can they get what they need?'
Nicholas R, Vora A, Hobart JC, Malik O & Reynolds R Nicholas R, Vora A, Hobart JC, Malik O & Reynolds R 'The multiple sclerosis impact scale is sensitive to factors predictive of increasing severity of multiple sclerosis'
Warner M, Baron RA, Ingram WM, Vickery PJ, Reilly S, Wright DE, Zajicek JP & Hobart JC Warner M, Baron RA, Ingram WM, Vickery PJ, Reilly S, Wright DE, Zajicek JP & Hobart JC 'Does the GHQ-30 leave room for change?' Author Site
Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ & Zajicek JP Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ & Zajicek JP 'Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88)' Author Site
Cano SJ, Hobart JC, Hart PE, Kolipara LVP, Schapira AHV & Cooper JM Cano SJ, Hobart JC, Hart PE, Kolipara LVP, Schapira AHV & Cooper JM 'International co-operative ataxia rating scale (ICARS): Suitable for clinical practice and treatment trials in Friedreich's ataxia?'
Ingram WM, Hobart JC, Reilly SM, Vickery PJ, Wright DE & Zajicek JP Ingram WM, Hobart JC, Reilly SM, Vickery PJ, Wright DE & Zajicek JP 'Introducing the south west impact of multiple sclerosis (SWIMS) project: A population-based natural history project to acquire patient-orientated information about the impact of multiple sclerosis'
Hobart JC, Styles IM, Baron R, Thompson AJ & Andrich D Hobart JC, Styles IM, Baron R, Thompson AJ & Andrich D 'Is it Rasch to compare thee on another scale?'
Baron R & Hobart J Baron R & Hobart J 'Laughing all the way to the item bank: How to improve your treatment effect by improving your outcome measurement'
Baron R, Ingram W, Warner M, Vickery PJ, Wright DE, Zajicek J & Hobart JC Baron R, Ingram W, Warner M, Vickery PJ, Wright DE, Zajicek J & Hobart JC 'Meaningless statistics and the illusion of fatigue' Author Site
Hobart JC, Zajicek JP & Thompson AJ Hobart JC, Zajicek JP & Thompson AJ 'Rating scales for neurological diseases: Lessons from Rasch analysis'
Cano SJ, Riazi A, Cooper JM, Schapira AHV & Hobart JC Cano SJ, Riazi A, Cooper JM, Schapira AHV & Hobart JC 'The Friedreich's Ataxia impact scale (FAIS) meets the needs of today's clinical studies'
Baron R, Zajicek J, Wright D, Vickery J, Ingram W, Reilly S & Hobart J Baron R, Zajicek J, Wright D, Vickery J, Ingram W, Reilly S & Hobart J 'Confounding the confused: Is measuring the frequency and severity of cognitive impairment really necessary?'
Hobart JC, Zajicek JP & Thompson AJ Hobart JC, Zajicek JP & Thompson AJ 'Developing rating scales for neurological diseases: Lessons from Rasch analysis'
Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ & Zajicek JP Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ & Zajicek JP 'Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88)' , DOI
Hobart JC, Styles IM, Baron R, Thompson AJ & Andrich D Hobart JC, Styles IM, Baron R, Thompson AJ & Andrich D 'Is it Rasch to compare thee on another scale?'
Baron R & Hobart J Baron R & Hobart J 'Laughing all the way to the item bank: how to improve your treatment effect by improving your outcome measurement'
Baron R, Zajicek J, Wright D, Vickery J, Ingram W & Hobart J Baron R, Zajicek J, Wright D, Vickery J, Ingram W & Hobart J 'Confounding the confused: is measuring the frequency and severity of cognitive impairment really necessary?'
Hobart JC, Andrich D, Zajicek JP & Thompson AJ Hobart JC, Andrich D, Zajicek JP & Thompson AJ 'Developing rating scales for multiple sclerosis: lessons from Rasch analysis'
Hobart J, Riazi A, Thompson A, Styles I, Ingram W, Vickery J, Warner M, Fox P & Zajicek J Hobart J, Riazi A, Thompson A, Styles I, Ingram W, Vickery J, Warner M, Fox P & Zajicek J 'Getting the measure of spasticity in MS: the multiple sclerosis spasticity scale' , DOI
Chataway J, Porter B, Hobart J, Heaney D, Riazi A & Thompson AJ Chataway J, Porter B, Hobart J, Heaney D, Riazi A & Thompson AJ 'Home or away? A randomised controlled trial of treating acute multiple sclerosis relapses with intravenous steroids'
Ingram W, Hobart J, Reilly S, Vickery P, Wright D & Zajicek J Ingram W, Hobart J, Reilly S, Vickery P, Wright D & Zajicek J 'Introducing the South West Impact of Multiple Sclerosis Project: a patient-focused natural history study of multiple sclerosis'
Hobart J, Styles L, Baron R, Thompson A & Andrich D Hobart J, Styles L, Baron R, Thompson A & Andrich D 'Is it Rasch to compare thee on another scale?'
Baron R, Ingram W, Warner M, Vickery J, Wright D, Zajicek J & Hobart J Baron R, Ingram W, Warner M, Vickery J, Wright D, Zajicek J & Hobart J 'Meaningless statistics and the illusion of fatigue measurement' , DOI
Nicholl L, Hobart J, Cramp F & Lowe-Strong AS Nicholl L, Hobart J, Cramp F & Lowe-Strong AS 'The Leeds Multiple Sclerosis Quality of Life Scale: a further psychometric evaluation'
Zajicek J, Thompson A & Hobart J Zajicek J, Thompson A & Hobart J 'Clinical trials in multiple sclerosis - The importance of the outcome measure'
Cano SJ, Warner TT, Fitzpatrick R, Bhatia K, Thompson AJ & Hobart JC Cano SJ, Warner TT, Fitzpatrick R, Bhatia K, Thompson AJ & Hobart JC 'The cervical dystonia impact profile (CDIP-58): A new patient-based rating scale'
Zajicek J, Thompson A & Hobart J Zajicek J, Thompson A & Hobart J 'Cutting the cost and length of clinical trials - the importance of choosing the right outcome measure'
Hobart J, Cano S, O'Connor R, Kinos S, Heinzlef O, Roullet E, Polman C, Uitdehaag B, McGuigan C & Hutchinson M Hobart J, Cano S, O'Connor R, Kinos S, Heinzlef O, Roullet E, Polman C, Uitdehaag B, McGuigan C & Hutchinson M 'Clinical trials in neurology: Are rating scales stable across European countries?'
Edwards SGM, Playford ED, Hobart JC & Thompson AJ Edwards SGM, Playford ED, Hobart JC & Thompson AJ 'Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation'
Carroll C, Hobart J, Fox C, Teare L & Gibson J Carroll C, Hobart J, Fox C, Teare L & Gibson J 'Stroke in Devon: The need to translate knowledge into action'
Barrett LE, Cano SJ, Thompson AJ, Zajicek JP & Hobart JC Barrett LE, Cano SJ, Thompson AJ, Zajicek JP & Hobart JC 'Myths about rating scales: There is a magic number of response categories'
Hobart J, Riazi A, Lamping D, Fitzpatrick R & Thompson AJ Hobart J, Riazi A, Lamping D, Fitzpatrick R & Thompson AJ 'Evaluating the use of B-INTERFERON in the UK: From whose perspective?'
Hobart JC & Cano SJ Hobart JC & Cano SJ 'Effect sizes can be misleading: Is it time to change the way we measure change?'
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M, Giovannoni G & MacDougall A Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M, Giovannoni G & MacDougall A 'Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study' Author Site , DOI
Barbic S, Hobart J, Barbic D, Bartlett S, Bingham C & Mathias S Barbic S, Hobart J, Barbic D, Bartlett S, Bingham C & Mathias S 'Strengthening scale development for clinical practice: recommendations for the next decade' Author Site , DOI
Baron R, Hobart JC, Zajicek J & Ingram W Baron R, Hobart JC, Zajicek J & Ingram W 'CONFOUNDING THE CONFUSED: IS MEASURING THE FREQUENCY AND SEVERITY OF COGNITIVE IMPAIRMENT REALLY NECESSARY'
Hobart J, Pesch VV, Rovira A, Alroughani R, Cutter G, Craveiro L, Dzhenkova D, Kuenzel T, Kantaria R & Trojano M Hobart J, Pesch VV, Rovira A, Alroughani R, Cutter G, Craveiro L, Dzhenkova D, Kuenzel T, Kantaria R & Trojano M '036  Ocrelizumab real-world effectiveness in patients with relapsing and primary progressive multiple sclerosis: MuSicalE baseline data' , DOI
Rog D, Hobart J, Clements J, McGregor J, Mazibrada G, Rajkumar A & Mathews J Rog D, Hobart J, Clements J, McGregor J, Mazibrada G, Rajkumar A & Mathews J '106  (NOT) comparing apples with apples; MS hospital episode statistics dashboard highlights variation in trusts’ reporting' , DOI
Rog D, Hobart J & Mathews J Rog D, Hobart J & Mathews J '107  The UK multiple sclerosis service and DMT prescribing audit of 70 centres: overview' , DOI
Rog D, Mathews J & Hobart J Rog D, Mathews J & Hobart J '108  UK multiple sclerosis service and DMT audit of 70 centres: variation in DMT prescribing' , DOI
Rog D, Hobart J & Mathews J Rog D, Hobart J & Mathews J '110  UK multiple sclerosis service audit of 70 centres: MS-MDTs' , DOI
Rog D, Hobart J & Mathews J Rog D, Hobart J & Mathews J '111  UK Multiple Sclerosis service audit of 70 centres: caseloads, patient lists and databases' , DOI
Giovannoni G, Hobart J, Mazibrada G, Bateman K & Marta M Giovannoni G, Hobart J, Mazibrada G, Bateman K & Marta M '125  Towards an optimal multiple sclerosis patient case-load for a full-time MSologist' , DOI
Rog D, Hobart J & Mathews J Rog D, Hobart J & Mathews J '150 The 70 UK centre multiple sclerosis service and DMT prescribing audit: practical project solutions' , DOI
Schmierer K, Redha I, Hammond V, Baker D, Barkhof F, Hooper R, Rashid W, Singh-Curry V, Hobart J & Giovannoni G Schmierer K, Redha I, Hammond V, Baker D, Barkhof F, Hooper R, Rashid W, Singh-Curry V, Hobart J & Giovannoni G '152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis' , DOI
Schmierer K, Baker D, Nawaz T, Allen-Philbey K, Barkhof F, Chataway J, Hooper R, Mihaylova B, Hobart J & Pavitt S Schmierer K, Baker D, Nawaz T, Allen-Philbey K, Barkhof F, Chataway J, Hooper R, Mihaylova B, Hobart J & Pavitt S '153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS)' , DOI
Kirsch B, Chadha D, Burke L & Hobart J Kirsch B, Chadha D, Burke L & Hobart J '18206 Hyperhidrosis Disease Severity Measure–Axillary: Evaluation of measurement properties in phase II study data' , DOI
Hobart J Hobart J '20 years of MSIS-29-importance of an MS specific QoL scale' Author Site , DOI
Hobart J & Burke L Hobart J & Burke L 'Advancing walking measurement in multiple sclerosis clinical trials: a new patient-reported outcome measure' Author Site , DOI
Gallagher PJ, McGuigan C, Nicholas R, Hobart J, Ford H, Petheram K, Sharrack B, Robertson N, Mazibrada G & Scolding N Gallagher PJ, McGuigan C, Nicholas R, Hobart J, Ford H, Petheram K, Sharrack B, Robertson N, Mazibrada G & Scolding N 'Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS)' Author Site , DOI
Gallagher P, McGuigan C, Nicholas R, Hobart J, Ford H, Petheram K, Sharrack B, Robertson N, Mazibrada G & Scolding N Gallagher P, McGuigan C, Nicholas R, Hobart J, Ford H, Petheram K, Sharrack B, Robertson N, Mazibrada G & Scolding N 'Alemtuzumab after natalizumab SWitch in evolving rapidly severe multiple sclerosis (ANSWERS MS): long-term UK & Ireland experience' Author Site , DOI
Ziemssen T, Bass AD, Berkovich R, Eichau S, Hobart J, Hunter SF, Limmroth V, Pelletier D, Pozzilli C & Schippling S Ziemssen T, Bass AD, Berkovich R, Eichau S, Hobart J, Hunter SF, Limmroth V, Pelletier D, Pozzilli C & Schippling S 'Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)' Author Site , DOI
Wu Y, Gandhi SK, Hobart J, Cutter G & Grinspan A Wu Y, Gandhi SK, Hobart J, Cutter G & Grinspan A 'Assessment of treatment satisfaction in multiple sclerosis: a review of the literature' Author Site , DOI
Van Wijmeersch B, Patti F, Hobart J, Kizlaitiene R, Vanderdonckt P, Shor S, Andreasen AK & Uitdehaag BM Van Wijmeersch B, Patti F, Hobart J, Kizlaitiene R, Vanderdonckt P, Shor S, Andreasen AK & Uitdehaag BM 'Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting' Author Site , DOI
Giovannoni G, Butzkueven H, Costello K, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C & Traboulsee A Giovannoni G, Butzkueven H, Costello K, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C & Traboulsee A 'Brain health: time matters in multiple sclerosis - developmental process and objectives of international consensus policy recommendations' Author Site , DOI
Hendy P, Heerasing N, Walker G, Heap G, Bewshae C, Kennedy N, Goodhand J, Martin R, Hobart J & Harrower T Hendy P, Heerasing N, Walker G, Heap G, Bewshae C, Kennedy N, Goodhand J, Martin R, Hobart J & Harrower T 'Clinical features of demyelination following anti-TNF alpha therapy' Author Site , DOI
Hobart J Hobart J 'Clinical outcomes assessment in MS trials: on balance, the Berg Balance Scale is a precarious measure' Author Site , DOI
Ontaneda D, Tallantyre E, Nakamura K, Planchon SM, Miller DM, Hersh C, Chaudhry BZ, Bale C, Alvarez E & Chataway J Ontaneda D, Tallantyre E, Nakamura K, Planchon SM, Miller DM, Hersh C, Chaudhry BZ, Bale C, Alvarez E & Chataway J 'Design and rationale of the determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis (DELIVER-MS) trial' Author Site , DOI
Hupperts R, Hobart J, Gasperini C, Lycke J, Ziemssen T, Feys P, McNeill M, Acosta C & Meergans M Hupperts R, Hobart J, Gasperini C, Lycke J, Ziemssen T, Feys P, McNeill M, Acosta C & Meergans M 'Efficacy of prolonged-release fampridine vs placebo on walking ability, dynamic and static balance and quality-of-life: an integrated analysis of MOBILE and ENHANCE' Author Site , DOI
Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G 'Engaging Multiple Stakeholder Groups in the Development of Standards for Multiple Sclerosis Care: A Modified Delphi Process' Open access
Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G 'Expert consensus on standards for multiple sclerosis care: results from a modified Delphi process' Author Site , DOI
Butzkueven H, Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G Butzkueven H, Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G 'Expert consensus on standards for multiple sclerosis care: results from a modified delphi process' , DOI
Skromne E, Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G Skromne E, Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G 'Expert consensus on standards for multiple sclerosis care: Results from a modified Delphi process' Author Site , DOI
Hobart J, Hupperts R, Linnebank M, Acosta C, McNeill M & Lima G Hobart J, Hupperts R, Linnebank M, Acosta C, McNeill M & Lima G 'Health-related quality of life improved in people with multiple sclerosis who had clinically meaningful changes in walking ability with PR-Fampridine: Post hoc analysis of enhance' , DOI
Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T, Kobelt G & Ziemssen T Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T, Kobelt G & Ziemssen T 'Implementing quality recommendations in multiple sclerosis care - a strategic approach to improve brain health' Author Site , DOI
Laverty J, Harford M, Magecha M, Parsons P, Thomas A, Ledsam J, Hobart J, Dennett R & Freeman J Laverty J, Harford M, Magecha M, Parsons P, Thomas A, Ledsam J, Hobart J, Dennett R & Freeman J 'Investigating referral patterns to Physiotherapy and Occupational Therapy: A clinical audit' Author Site , DOI
Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T, Kobelt G & Ziemssen T Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T, Kobelt G & Ziemssen T 'Maximizing Brain Health in Multiple Sclerosis: A Quality Improvement Framework' Author Site , DOI
Hobart J, Thangavelu K, Hass S, Chowdhury S & Rufi P Hobart J, Thangavelu K, Hass S, Chowdhury S & Rufi P 'Measuring treatment satisfaction in patients with RMS in the real world: is the TSQM fit for purpose? An evaluation using Teri-PRO study data' Author Site , DOI
Parker S, Burke L & Hobart J Parker S, Burke L & Hobart J 'Measuring upper limb function in multiple sclerosis clinical trials: definition, conceptualisation and measurement' Open access
Trojano M, Hobart J, Kobelt G, Pesch VV, Rovira A, Kantaria R, Craveiro L, Dzhenkova D, Wei W & Alroughani R Trojano M, Hobart J, Kobelt G, Pesch VV, Rovira A, Kantaria R, Craveiro L, Dzhenkova D, Wei W & Alroughani R 'Novel Assessment of Real-world Effectiveness of Ocrelizumab for Treatment of Patients with Relapsing and Primary Progressive Multiple Sclerosis: Design of a Multicenter Non-interventional Study (musicale Study)' , DOI
Giovannoni G, Airas L, Bove R, Boyko A, Cutter G, Hobart J, Kuhle J, Oh J, Tur C & Garas M Giovannoni G, Airas L, Bove R, Boyko A, Cutter G, Hobart J, Kuhle J, Oh J, Tur C & Garas M 'Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design' Author Site , DOI
Giovannoni G, Airas L, Bove R, Boyko A, Cutter G, Hobart J, Kuhle J, Oh J, Tur C & Garas M Giovannoni G, Airas L, Bove R, Boyko A, Cutter G, Hobart J, Kuhle J, Oh J, Tur C & Garas M 'Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design' Author Site
Van Wijmeersch B, Harrower T, Hobart J, Kizlaitiene R, Marfia GA, Patti F, Pearson OR, Van Pesch V, Vanderdonckt P & Vecsei L Van Wijmeersch B, Harrower T, Hobart J, Kizlaitiene R, Marfia GA, Patti F, Pearson OR, Van Pesch V, Vanderdonckt P & Vecsei L 'One-Year Interim Analysis of Health-Related Quality of Life in RRMS Patients Treated With Alemtuzumab in a Real-world Clinical Setting (LemQoL Study)' Author Site , DOI
Hendy P, Heerasing N, Walker G, Goodhand J, Harrower T, Hobart J, Spiers A, Coles A, Martin R & Ahmad T Hendy P, Heerasing N, Walker G, Goodhand J, Harrower T, Hobart J, Spiers A, Coles A, Martin R & Ahmad T 'PO132 Clinical features of demyelination following anti-tnfΑ therapy' , DOI
Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G Hobart J, Bowen A, Eberhard L, Pepper G & Giovannoni G 'International consensus on quality standards for multiple sclerosis care: results from a modified Delphi process' Author Site , DOI Open access
Hobart J, Cleanthous S, Zajieck J & Cano S Hobart J, Cleanthous S, Zajieck J & Cano S 'CONFUSION IN CLINICAL TRIALS OF ALZHEIMER'S DISEASE' , DOI
Giovannoni G, White S, Mistry N, Calhoun S, Young C, Coutts M, Roberts M, Anderson P, Bernstein R & Hobart J Giovannoni G, White S, Mistry N, Calhoun S, Young C, Coutts M, Roberts M, Anderson P, Bernstein R & Hobart J '163 Development of clinical and patient-reported quality metrics for multiple sclerosis: a UK pilot study report' , DOI Open access
Atwal P, Brown Hajdukova E, Girardi A, Jarodia K, Rzepa E, Rudell K, Abetz-Webb L & Hobart J Atwal P, Brown Hajdukova E, Girardi A, Jarodia K, Rzepa E, Rudell K, Abetz-Webb L & Hobart J 'POSC2 A Case Study: Evaluation of the Infantile Neuroaxonal Dystrophy Rating Scale (INAD-RS)' , DOI
Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman A, Farrell R, Hupperts R, Englishby V, McNeill M & Chang I Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman A, Farrell R, Hupperts R, Englishby V, McNeill M & Chang I 'Prolonged-release fampridine demonstrates rapid and sustained clinically meaningful improvements in walking ability over 24 weeks: MSWS-12 responders in the ENHANCE study' Author Site , DOI
AlMasri O & Hobart J AlMasri O & Hobart J '176 Fingolimod associated immune haemolytic anaemia' , DOI
Hendy P, Heerasing N, Walker G, Heap G, Bewshea C, Kennedy N, Goodhand J, Harrower T, Hobart J & Spiers A Hendy P, Heerasing N, Walker G, Heap G, Bewshea C, Kennedy N, Goodhand J, Harrower T, Hobart J & Spiers A 'PWE-066 Clinical features of demyelination during anti-tnf therapy: preliminary outcomes of the pred4 study' , DOI
Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman A, Farrell R, Englishby V, McNeill M, Chang I & Mehta L Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman A, Farrell R, Englishby V, McNeill M, Chang I & Mehta L 'Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study' Author Site , DOI
Burke L, Hobart JC, Fox K, Lehrer-Graiwer J, Bridges K, Kraus M & Ramos E Burke L, Hobart JC, Fox K, Lehrer-Graiwer J, Bridges K, Kraus M & Ramos E 'The 10-Item Sickle Cell Disease Severity Measure (SCDSM-10): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor' , DOI
Carroll W, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T Carroll W, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T 'Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access' Author Site , DOI
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T 'Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access' Author Site
Comi G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T Comi G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A & Vollmer T 'Time matters in multiple sclerosis international consensus recommendations on diagnosis, management, and treatment access' Author Site , DOI
Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Pepper G, Thalheim C, Traboulsee A & Vollmer T Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Pepper G, Thalheim C, Traboulsee A & Vollmer T 'Time matters in multiple sclerosis-International consensus policy recommendations on diagnosis, management, and treatment access' Author Site , DOI
Hobart J, Butzkueven H, Haartsen J, Vollmer T, Ziemssen T, Lane T & Giovannoni G Hobart J, Butzkueven H, Haartsen J, Vollmer T, Ziemssen T, Lane T & Giovannoni G 'Timely intervention, monitoring and education MATTERS in multiple sclerosis (TIME MATTERS in MS): developing a globally applicable quality improvement tool' Author Site , DOI
Rog D, Hobart J & Matthews J Rog D, Hobart J & Matthews J 'UK Multiple Sclerosis service audit of 70 centres: access to neuroradiology' , DOI
Mathews J, Rog D & Hobart J Mathews J, Rog D & Hobart J 'Addressing the MS care paradox: practical solutions' Author Site , DOI
Hobart J, O'Brien L, Andrich D & Giovannoni G Hobart J, O'Brien L, Andrich D & Giovannoni G 'Multiple sclerosis science: a unique opportunity to advance scientific developments and patient care' Author Site , DOI
Hobart J, Vo P, Ryan S, Arnould S & Burke L Hobart J, Vo P, Ryan S, Arnould S & Burke L 'Patient-reported outcomes in multiple sclerosis clinical trials: Measurement lessons from the EXPAND study' Author Site , DOI
Eelen P, Hobart J, Bharadia T, Chitnis T, Bauer B, Lloyd A, Schmidt H, Fitzgerald J, King M & Vandercappellen J Eelen P, Hobart J, Bharadia T, Chitnis T, Bauer B, Lloyd A, Schmidt H, Fitzgerald J, King M & Vandercappellen J 'Other Patient reported outcomes for MS studies - a successful marriage of scientific requirements and patient preference?' Author Site , DOI
Hobart J, King T, Close J, Hutchings J & Thompson A Hobart J, King T, Close J, Hutchings J & Thompson A 'Measuring patient-reported upper limb function in multiple sclerosis clinical trials: Can item banks achieve measurement nirvana?' Author Site , DOI
Hobart J, Mathews J & Rog D Hobart J, Mathews J & Rog D 'The UK multiple sclerosis care crisis: an audit of 70 services' Author Site , DOI
Hobart J, Butzkueven H, Haartsen J, Ziemssen T, Lane T & Giovannoni G Hobart J, Butzkueven H, Haartsen J, Ziemssen T, Lane T & Giovannoni G 'Timely Intervention, Monitoring and Education MATTERS in MS (TIME MATTERS in MS): global applicability of the MS Brain Health quality improvement tool' Author Site , DOI
Hobart J, Butzkueven H, Haartsen J, Vollmer T, Ziemssen T, Lane T & Giovannoni G Hobart J, Butzkueven H, Haartsen J, Vollmer T, Ziemssen T, Lane T & Giovannoni G 'Timely intervention, monitoring and education matters in ms (time matters in ms): global piloting of the ms brain health quality improvement tool' Author Site , DOI
Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M, Giovannoni G & MacDougall A Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M, Giovannoni G & MacDougall A 'Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study' Author Site , DOI
Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Blain C, De Luca G, Evangelou N, Ford HL & Gallagher P Dobson R, Craner M, Waddingham E, Miller A, Cavey A, Blain C, De Luca G, Evangelou N, Ford HL & Gallagher P 'Differences between clinical trials and "real-world" use of disease modifying therapies: insights from the UK OPTIMISE:MS pharmacovigilance study' Author Site , DOI
Francis A, Gomez E, Chen B, Woodhall M, Blain C, Cooper S, Dobson R, Fisniku L, Halfpenny C & Hobart J Francis A, Gomez E, Chen B, Woodhall M, Blain C, Cooper S, Dobson R, Fisniku L, Halfpenny C & Hobart J 'Predicting the risk of long-term relapse in MOGAD' Author Site , DOI
Trojano M, Meuth S, Buttmann M, Weber MS, Van Pesch V, Alroughani R, Rovira A, Cutter G, Hobart J & Sierzega M Trojano M, Meuth S, Buttmann M, Weber MS, Van Pesch V, Alroughani R, Rovira A, Cutter G, Hobart J & Sierzega M 'SARS-CoV-2 vaccination and COVID-19 infections in people with multiple sclerosis treated with ocrelizumab in the prospective, multicenter, noninterventional MuSicalE and CONFIDENCE studies' Author Site , DOI
Trojano M, Van Pesch V, Al Roughani R, Rovira A, Cutter G, Dzhenkova D, Hagenbuch N, Kantaria R, Craveiro L & Hobart J Trojano M, Van Pesch V, Al Roughani R, Rovira A, Cutter G, Dzhenkova D, Hagenbuch N, Kantaria R, Craveiro L & Hobart J 'The real-world effectiveness of ocrelizumab for treating patients with MS: 1-year data from the MuSicalE study' Author Site , DOI
Girardi A, Hobart J, Hajdukova BE & Rudell K Girardi A, Hobart J, Hajdukova BE & Rudell K 'COA DEVELOPMENT AND EVALUATION IN RARE DISEASE: A NARRATIVE REVIEW' Author Site , DOI
Hobart J, Piani-Meier D, Cree B, Giovannoni G, Kappos L, Fox RJ, Bar-Or A, Maca J, Arnould S & Karlsson G Hobart J, Piani-Meier D, Cree B, Giovannoni G, Kappos L, Fox RJ, Bar-Or A, Maca J, Arnould S & Karlsson G 'Effect of Siponimod on the MSWS-12 and MSIS-29 in Patients With SPMS From the EXPAND Study' Author Site , DOI
Bharadia T, Chitnis T, Eelen P, Bauer B, Brichetto G, Lloyd A, Schmidt H, King M, Fitzgerald J & Hach T Bharadia T, Chitnis T, Eelen P, Bauer B, Brichetto G, Lloyd A, Schmidt H, King M, Fitzgerald J & Hach T 'Patient-reported Outcomes used in Multiple Sclerosis Trials: Critical Assessment and Insights from People Living with MS' Author Site , DOI
Lieberman D, Mangat H, Allen-Philbey K, Baker D, Barkhof F, Chandran S, Chapman C, Chataway J, Ford H & Giovannoni G Lieberman D, Mangat H, Allen-Philbey K, Baker D, Barkhof F, Chandran S, Chapman C, Chataway J, Ford H & Giovannoni G 'Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS)' Author Site , DOI
Kirsch B, Chadha D, Burke L & Hobart J Kirsch B, Chadha D, Burke L & Hobart J 'Hyperhidrosis Disease Severity Measure-Axillary: Evaluation of measurement properties in phase II study data' Author Site
Kobelt G, Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T & Ziemssen T Kobelt G, Hobart J, Alexander M, Bowen A, Butzkueven H, Giovannoni G, Kenny T & Ziemssen T 'Maximizing brain health in multiple sclerosis: a quality improvement framework' Author Site
Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman A, Farrell R, Englishby V, McNeill M, Chang I & Mehta L Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman A, Farrell R, Englishby V, McNeill M, Chang I & Mehta L 'Prolonged-Release Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial' Author Site